The regulator says Merck needs to focus on lower doses of the drug.
Business briefs: Bayer, FDA, Ranbaxy
May 15, 2013
7:13 pm
Bayer’s prostate cancer drug clears FDA three months early; a House committee is pressing the regulator for employment transparancy; and Ranbaxy takes a multi-million dollar hit over violations
Navidea deploying MSLs in launch of new diagnostic agent
Medical science liaisons will educate nuclear-medicine clinicians as part of the launch of a new Navidea diagnostic agent for use in breast and skin cancer.
Excedrin relaunch features Sparks, “Thank yous” from migraine sufferers
Novartis is hyping its relaunch of Excedrin with a celebrity spokesperson, a migraine app and a survey of women migraine sufferers – along with print and out-of-home ads, radio promotions, direct mail and social media.
Company news: Eli Lilly and Novartis
October 31, 2012
2:56 pm
Eli Lilly to add manufacturing capacity in Indianapolis, Novartis invests more in Singapore
The deadly meningitis outbreak highlights the threat not only to public health, but also to the pharma industry, posed by the largely unregulated practice of pharmacy compounding.
Company news: UBM Medica, Bristol-Myers Squibb
July 11, 2012
5:53 pm
UBM Medica adds a third iPad app, BMS expands in Puerto Rico.
Company news: GlaxoSmithKline, AstraZeneca, Nature Publishing
March 22, 2012
3:52 pm
GlaxoSmithKline is building its first new UK factory in almost 40 years, the firm said, spurring jobs while breaking new ground at some of its current locations.
Sanofi is girding itself for an ugly year, forecasting a 12%-15% drop in business earnings per share for 2012 as the company absorbs the loss of patent exclusivity on a stable of drugs that brought in more than €4 billion last year.
J&J says no shakeup at McNeil Consumer Healthcare unit
J&J is pushing back hard against a Wall Street Journal article suggesting that a pair of retirements and a promotion are part of a corporate shakeup of its recall-plagued McNeil Consumer Healthcare division.